Abstracts (NSCLC). Using data from the SEER-Medicare cancer registry, we examined trends in use, outcomes, and costs of care for NSCLC patients receiving chemotherapy in community settings from [1994][1995][1996][1997][1998][1999][2000][2001]. METHODS: Patients were included if they were diagnosed with locally advanced or metastatic (TNM stages IIIb and IV) NSCLC between 1 January 1994 and 31 December 2001. Patients were stratified based on initial chemotherapy agent(s) used. Cox proportional hazards models were used to compare survival as a function of initial chemotherapy regimen, controlling for age, sex, race, noncancer comorbidity, stage at diagnosis, SEER region, and receipt of cancer-related surgery or radiation therapy in the first 3 months following diagnosis. Lifetime medical costs were calculated for each chemotherapy group using the Kaplan Meier sample average estimator. RESULTS: A total of 14,875 met inclusion criteria, 7411 (49.8%) stage IIIb and 7464 (50.2%) stage VI at diagnosis. Chemotherapy use in the first 3 months following diagnosis increased from 21% to 43% of those diagnosed over the observation period (p < 0.01). Persons > = 75 (OR = 0.91), females (OR = 0.87), African Americans (OR = 0.49) and those with >1 comorbidity (OR = 0.84) were significantly less likely to receive chemotherapy. 
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PCN8 OUTCOMES AND COSTS OF SURROGATE END-POINTS (SES) AND BIOMARKERS IN PHASE I ONCOLOGY CLINICAL TRIALS
Goulart BHL, Roberts TG, Liu Y, Clark JW Massachusetts General Hospital, Boston, MA, USA OBJECTIVES: Targeted therapies, functional imaging and translational research have enabled utilization of a new endpoint in phase I oncology trials, known as Surrogate Endpoints (SEs) or biomarkers. Investigators hope that SEs will improve the efficiency of drug-development. However, whether SEs can substitute for traditional endpoints is unknown. The role of SEs in drug selection, target validation, dosing and schedule is not defined. METHODS: We analyzed phase I single-agent abstracts in PASCO from 1992 to 2002 that included at least one SE. Subsequent publications were analyzed based on the primary SE. Drugs were classified as cytotoxic, biologic, or targeted and SEs classified by their technology (imaging, blood biomarkers or advanced histology). We designed 4 questions to evaluate the role of SEs, beginning with: "Did the SE help . . . : 1) ". . . determine the dose for phase II?"; 2) ". . . in finding the schedule?"; 3) ". . . with the author's conclusions?"; and 4) ". . . validate that the target was affected?". McNemar's and chi-square tests compared the utility of SEs across these questions and across drug classes, respectively. We also related the budgets of 18 institutional trials to their number of SEs. RESULTS: Of 74 trials, 57% tested biologics, 24% small molecules, 14% cytotoxic and 5% other. According to technology: 68% were blood studies, 24% histologic analysis, and 7% imaging. The frequency of "yes" for the 4 questions was 15%, 16%, 38%, and 62%, respectively (p < 0.001 between questions), without differences between classes. The budgeted cost of adding a SE was US$6675 per patient.
CONCLUSIONS:
SEs modestly aided in defining dose and schedule for future studies and in the overall drug-development process. They helped in validating that the therapy affected the intended target. Better preclinical evaluation of SEs may enhance their utility. Further research should help define how best to incorporate SEs into trial design.
PCN9 COST EFFECTIVENESS OF ADDING BISPHOSPHONATES TO THE NON-SURGICAL ANDROGEN DEPRIVATION THERAPY FOR FRACTURE REDUCTION IN PATIENTS WITH NON-METASTATIC PROSTATE CANCER
Phatak HM, Thomas III J Purdue University, West Lafayette, IN, USA OBJECTIVES: Prostate Cancer patients using Androgen Deprivation Therapy (ADT) are considered at a higher risk for osteoporotic fractures due to excessive loss of bone mineral density (BMD). This study measured the incremental Cost Effectiveness (CE) of adding bisphosphonates to ADT based on QALYs gained. METHODS: A Markov model of fracture-risk associated with osteoporosis in patients with non-metastatic prostate cancer was developed to compare the incremental CE of adding pamidronate or zoledronic acid to ADT. Literature-based estimates of costs of treating osteoporotic fractures and average wholesale prices of bisphosphonates were used. Disutilities published by the National Osteoporotic Foundation for the first and subsequent year following an osteoporotic fracture were used to measure effectiveness of prescribing bisphosphonates. Robustness of assumptions was tested using deterministic and stochastic sensitivity analyses. RESULTS: The Markov analyses yielded total incremental cost of $17,009.40 for ADT + pamidronate and of $25,838.90 for ADT + zoledronic acid over ADT only option. Adding pamidronate resulted in a gain of 0.0128 QALYs at a marginal CE of $1,327,746 as compared to zoledronic acid which resulted in a gain of 0.015 QALYs at a marginal CE of $1,722,593. Monte Carlo simulation as well as one-way and two-way sensitivity analyses indicated robustness of the key assumptions such as probability of fracture, probability of death due to hip fracture and discount rate. CONCLUSIONS: In case of reducing the fracture-risk in non-metastatic prostate cancer patients using bisphosphonates resulted in nominal gain in QALYs at a very high marginal CEs for both drugs.
PCN10 THE COST-EFFECTIVENESS OF METHYL AMINOLEVULINATE PHOTODYNAMIC THERAPY (MAL-PDT) FOR BASAL CELL CARCINOMA
Orme ME, Howard P Heron Evidence Development, Letchworth, Herts, United Kingdom OBJECTIVES: Basal cell carcinoma (BCC) is a common malignant tumour, usually treated with surgery though the cosmetic appearance of the treated lesions can be poor. Methyl aminolevulinate cream is the first topical PDT therapy licensed in the UK for superficial, or mid-face, large or recurrent nodular BCC and can be considered for lesions unsuitable for surgery. The aim of this evaluation was to assess the cost-effectiveness of MAL-PDT versus excision. METHODS: Clinical outcomes were from a comparative trial of nodular BCC. The clinical response for MAL-PDT from a non-comparative trial of primary superficial BCC (Horn et al, in press) was also used to reflect the subgroup most likely to be treated with MAL-PDT. Lesion reoccurrence was derived from published literature and an expert Delphi panel provided resource use. The NHS perspective was taken and only direct costs were considered. Decision analysis was used with MAL-PDT or excision as first line therapy and, if no lesion response, second line therapy. A one-year time horizon was used to capture all relevant outcomes. Excellent cosmetic outcome was defined as 100% complete lesion response, with no scarring, atrophy or induration, and no or slight occurrence of redness or change in pigmentation compared to adjacent skin. Clinical data from the trials were subjected to stochastic sensitivity analysis. RESULTS: From the deterministic model, 69% of nodular BCC patients had an excellent cosmetic outcome with MAL-PDT at a cost of £988.47 per patient compared to 36% of patients treated by excision (£772.91 per patient). Substituting the superficial BCC efficacy data, the cost of MAL-PDT was found to be £890.35 with a 75% excellent cosmetic outcome. In the stochastic analysis using 1000 simulations, 95% of the ICERs calculated were in the range £17 to £2816. CONCLUSIONS: MAL-PDT is advantageous for cosmetically sensitive areas such as lesions on the face and has comparable costs.
PCN11 COST-EFFECTIVENESS ANALYSIS OF DOSE-DENSE CHEMOTHERAPY WITH FILGRASTIM AS POSTOPERATIVE ADJUVANT TREATMENT OF BREAST CANCER
Yu AP, Hay JW University of Southern California, Los Angeles, CA, USA OBJECTIVES: Although higher density chemotherapy regimens could improve treatment outcomes, febrile neutropenia and its related complications often limit the density of chemotherapy administration to a suboptimal level. Filgrastim-enabled chemotherapy regimens administered at a high density were shown to increase survival among breast cancer patients in a recent clinical trial (Citron et al, 2003) . The high costs of filgrastim and time loss of patients and caregivers due to frequent administration, motivated an economic analysis to compare the cost-effectiveness of dose-dense therapy with filgrastim vs. conventional chemotherapy in breast cancer patients. METHODS: Target Population: Women with node-positive breast cancer. Time Horizon: Twelve cycles of chemotherapy with lifetime follow up. Perspective: Societal. Data Sources: The Intergroup Trial C9741 was the primary source of treatment efficacy, rates of febrile neutropenia with and without hospitalization, and other major toxicities. Direct health care cost components and indirect costs of patient and caregiver time loss were obtained from literature review. Measurements: Discounted lifetime costs were estimated based on a decision model. Discounted qualityadjusted life years (QALYs) was estimated based on the DEALE method. Incremental cost-effectiveness ratios (ICERs) were calculated for each age group at 5-year interval. RESULTS: Under the base case assumptions, dose-dense chemotherapy incurred cost $25,530 higher than conventional therapy over lifetime, and the average discounted survival benefits were 1.400 QALYs per patient. This resulted in an average cost-effectiveness ratio of $19,940 per QALY saved. ICERs were $13,672/QALY in age group 30-34, and this ratio increased with age to $34,418/ QALY in age group 75-80, indicating a more favorable costeffectiveness in younger women. Results of the model were relatively stable when the parameters changed within a reasonable range. CONCLUSIONS: From a societal prospective, dose-dense chemotherapy with filgrastim in breast cancer patients is a costeffective improvement compared to conventional chemotherapy. 
PCN12 ECONOMIC BURDEN OF PANCREATIC CANCER AND TREATMENT FAILURE

Chang
PCN13 AN ECONOMIC ANALYSIS OF RADIATION VERSUS RADIATION PLUS GOSERELIN IN THE TREATMENT OF LOCALLY ADVANCED PROSTATE CANCER
Taylor MD University of Florida, Gainesville, FL, USA OBJECTIVE: Clinical trial data has proven hormonal therapy increases survival time when added to a radiation treatment strategy for locally advanced prostate cancer. The purpose of this analysis was to assess from the payers' perspective the cost effectiveness of adding hormonal therapy to radiation therapy when treating patients with locally advanced prostate cancer. METHODS: A decision tree model incorporating a Markov process was developed using DATA 4.0 to determine the cost associated with a locally advanced prostate cancer patient gaining an additional year of life as a result of adding goserelin, a gonadotropin-releasing hormone agonist analogue, to a radiation treatment strategy. Data on the effectiveness of each strategy was obtained from published clinical trials. Costs were based on the literature and data from the US Centers for Medicaid and Medicare Services and the UK Department of Health. All costs and benefits were discounted at five percent. Conventional and probabilistic sensitivity analyses were used to assess model robustness. RESULTS: Over a 9-year period, expected costs of treatment with radiation alone and with radiation plus goserelin are $7582 and $25,299, respectively, leading to an incremental cost of $17,718 to add hormonal therapy to a radiation only treatment strategy. In terms of effectiveness, over a nineyear period, patients treated with hormonal therapy in addition to radiation therapy gain an average of 0.65 years of life. The incremental cost effectiveness of combination therapy over radiation alone is $30,887 per additional life-year gained. Varying
